Arbor Biotechnologies
Arbor Biotechnologies raises $215M Series C at $800M valuation
Arbor Biotechnologies: Series C Funding Round
Arbor Biotechnologies has successfully raised $215M in Series C funding, reaching a valuation of $800M.
Company Overview
Gene editing technologies
Funding Details
The Series C round was led by Lightspeed Venture Partners, with participation from Redmile Group, Agent Capital, Amplitude Ventures.
Company Information
- Headquarters: 830 Winter Street, Waltham, MA 02451
- Founded: 2016
- Employees: 100+
- Category: Biotech
Investment
Arbor Biotechnologies plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Lightspeed Venture Partners: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Agent Capital: Verified investor in Series C
- Amplitude Ventures: Verified investor in Series C
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free